Avid Bioservices Inc (CDMO)

[Krakonos]

exwannabe I do not understand why.

Second (and more importantly), your math fails to account for the simple fact that as the trial progresses there will (hopefully) be more patients at risk in the bavi arm, thus more deaths there than in the placebo arm.

Why would more patients be at risk compared with placebo group?

Logic tells me that trial can't progress forever, because placebo group will have all patients 6 ft under at some point PRIOR to bavi's arm.

What is it that I am missing?
Am I that dense?